BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24130882)

  • 1. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.
    Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC
    PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.
    Achyut BR; Angara K; Jain M; Borin TF; Rashid MH; Iskander ASM; Ara R; Kolhe R; Howard S; Venugopal N; Rodriguez PC; Bradford JW; Arbab AS
    Sci Rep; 2017 Oct; 7(1):13754. PubMed ID: 29062041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.
    Arrieta VA; Najem H; Petrosyan E; Lee-Chang C; Chen P; Sonabend AM; Heimberger AB
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
    Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
    Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.
    Gangoso E; Southgate B; Bradley L; Rus S; Galvez-Cancino F; McGivern N; Güç E; Kapourani CA; Byron A; Ferguson KM; Alfazema N; Morrison G; Grant V; Blin C; Sou I; Marques-Torrejon MA; Conde L; Parrinello S; Herrero J; Beck S; Brandner S; Brennan PM; Bertone P; Pollard JW; Quezada SA; Sproul D; Frame MC; Serrels A; Pollard SM
    Cell; 2021 Apr; 184(9):2454-2470.e26. PubMed ID: 33857425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
    Peshoff MM; Gupta P; Oberai S; Trivedi R; Katayama H; Chakrapani P; Dang M; Migliozzi S; Gumin J; Kadri DB; Lin JK; Milam NK; Maynard ME; Vaillant BD; Parker-Kerrigan B; Lang FF; Huse JT; Iavarone A; Wang L; Clise-Dwyer K; Bhat KP
    Neuro Oncol; 2024 May; 26(5):826-839. PubMed ID: 38237157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
    Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
    Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Microenvironment in Glioblastoma Subtypes.
    Chen Z; Hambardzumyan D
    Front Immunol; 2018; 9():1004. PubMed ID: 29867979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
    Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
    Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.